Alnylam Pharmaceuticals Inc. (ALNY) Cut to “Neutral” at JPMorgan Chase & Co.
JPMorgan Chase & Co. downgraded shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from an overweight rating to a neutral rating in a research note published on Thursday morning. JPMorgan Chase & Co. currently has $51.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $83.00.
Several other analysts have also issued reports on ALNY. Credit Suisse Group AG reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Leerink Swann reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Cowen and Company reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Needham & Company LLC reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 13th. Finally, FBR & Co reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Friday, June 10th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $80.88.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 35.52 on Thursday. The firm’s market capitalization is $3.04 billion. Alnylam Pharmaceuticals has a 12 month low of $33.16 and a 12 month high of $110.75. The company has a 50-day moving average price of $69.62 and a 200-day moving average price of $65.95.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same period in the prior year, the firm posted ($0.85) EPS. The company’s revenue for the quarter was up .2% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals will post ($4.68) EPS for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.00% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Dodge & Cox bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $139,650,000. Wellington Management Group LLP boosted its stake in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares in the last quarter. Bridger Management LLC acquired a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $50,041,000. Slate Path Capital LP boosted its stake in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock valued at $71,244,000 after buying an additional 410,000 shares in the last quarter. Finally, Deerfield Management Co. acquired a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $18,645,000. Institutional investors own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.